Immatics adds $150M ahead of anzu-cel readout
German biotech Immatics is raising $150 million (€128.6 million) through an underwritten offering to strengthen its balance sheet ahead of a pivotal readout for its lead cancer cell therapy, anzu-cel.
Why it matters: Anzu-cel is approaching its decisive clinical and regulatory milestones and Immatics is simultaneously expanding its Phase 3 programme and preparing for a potential commercial launch.
Backstory: Immatics recently revised the SUPRAME Phase 3 trial in previously treated advanced melanoma after disease progression and deaths occurred more slowly than initially modelled. The company will move directly to a final progression-free survival analysis, expected in the first half of 2027. It also plans to enrol about 90 additional patients, bringing the trial to approximately 450 participants, to strengthen the overall survival analysis. A US marketing application is planned for 2027.
Where the money could go: The offering announcement does not earmark the proceeds. However, Immatics’ latest business update points to the main capital needs: completing the enlarged SUPRAME trial, manufacturing anzu-cel, building commercial infrastructure and advancing its broader PRAME-targeted cell therapy and bispecific pipeline.
What’s next: Immatics already held $448.2 million (€393.4 million) in cash and other financial assets at the end of June, with runway projected into 2028. The new capital therefore provides an additional buffer through the anzu-cel readout, regulatory filing and launch preparations.
